Invesaro

Stocks Comparison

Amgen vs Gilead Sciences: revenue, profit, margins and growth compared

Amgen brought in $36.8B of revenue in fiscal 2025, Gilead Sciences $29.4B in fiscal 2025. Revenue changed by +10.0% at Amgen and +2.4% at Gilead Sciences on the year before, so Amgen grew faster. Amgen kept 21.0% of its revenue as net profit, Gilead Sciences 28.9%. Free cash flow was $8.1B at Amgen and $9.5B at Gilead Sciences.

Side by side, latest fiscal year

AMGNGILD
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$36.8B$29.4B
Revenue growth+10.0%+2.4%
Net income$7.7B$8.5B
Net margin21.0%28.9%
Free cash flow$8.1B$9.5B
Free cash flow margin22.0%32.1%
Earnings per share (diluted)$14.23$6.78
Cash$9.1B$7.6B
Debt$54.6B$24.9B
Price to earnings29.122.3
Market value$224.2B$187.1B
Dividend yield2.33%2.09%
Rank by revenue in sector#20 of 523 · Health care#22 of 523 · Health care

Over the years

Revenue
AMGN FY2018: $23.7BAMGN FY2019: $23.4BAMGN FY2020: $25.4BAMGN FY2021: $26BAMGN FY2022: $26.3BAMGN FY2023: $28.2BAMGN FY2024: $33.4BAMGN FY2025: $36.8BGILD FY2018: $22.1BGILD FY2019: $22.4BGILD FY2020: $24.7BGILD FY2021: $27.3BGILD FY2022: $27.3BGILD FY2023: $27.1BGILD FY2024: $28.8BGILD FY2025: $29.4BFY18FY19FY20FY21FY22FY23FY24FY25
AMGN $36.8BGILD $29.4B
Net income
AMGN FY2018: $8.4BAMGN FY2019: $7.8BAMGN FY2020: $7.3BAMGN FY2021: $5.9BAMGN FY2022: $6.6BAMGN FY2023: $6.7BAMGN FY2024: $4.1BAMGN FY2025: $7.7BGILD FY2018: $5.5BGILD FY2019: $5.4BGILD FY2020: $123MGILD FY2021: $6.2BGILD FY2022: $4.6BGILD FY2023: $5.7BGILD FY2024: $480MGILD FY2025: $8.5BFY18FY19FY20FY21FY22FY23FY24FY25
AMGN $7.7BGILD $8.5B
Net margin
AMGN FY2018: 35.3%AMGN FY2019: 33.6%AMGN FY2020: 28.6%AMGN FY2021: 22.7%AMGN FY2022: 24.9%AMGN FY2023: 23.8%AMGN FY2024: 12.2%AMGN FY2025: 21.0%GILD FY2018: 24.7%GILD FY2019: 24.0%GILD FY2020: 0.5%GILD FY2021: 22.8%GILD FY2022: 16.8%GILD FY2023: 20.9%GILD FY2024: 1.7%GILD FY2025: 28.9%FY18FY19FY20FY21FY22FY23FY24FY25
AMGN 21.0%GILD 28.9%
Revenue growth
AMGN FY2019: -1.6%AMGN FY2020: +8.8%AMGN FY2021: +2.2%AMGN FY2022: +1.3%AMGN FY2023: +7.1%AMGN FY2024: +18.6%AMGN FY2025: +10.0%GILD FY2019: +1.5%GILD FY2020: +10.0%GILD FY2021: +10.6%GILD FY2022: -0.1%GILD FY2023: -0.6%GILD FY2024: +6.0%GILD FY2025: +2.4%FY19FY20FY21FY22FY23FY24FY25
AMGN +10.0%GILD +2.4%
Free cash flow
AMGN FY2018: $10.6BAMGN FY2019: $8.5BAMGN FY2020: $9.9BAMGN FY2021: $8.4BAMGN FY2022: $8.8BAMGN FY2023: $7.4BAMGN FY2024: $10.4BAMGN FY2025: $8.1BGILD FY2018: $7.5BGILD FY2019: $8.3BGILD FY2020: $7.5BGILD FY2021: $10.8BGILD FY2022: $8.3BGILD FY2023: $7.4BGILD FY2024: $10.3BGILD FY2025: $9.5BFY18FY19FY20FY21FY22FY23FY24FY25
AMGN $8.1BGILD $9.5B

Fiscal years as each company reports them; the two may end in different months.

Questions about Amgen and Gilead Sciences

Which is bigger by revenue, Amgen or Gilead Sciences?

Amgen is bigger by revenue: $36.8B in fiscal 2025, against $29.4B for Gilead Sciences in fiscal 2025.

Which keeps more of its revenue as profit, Amgen or Gilead Sciences?

Amgen had a net margin of 21.0% in fiscal 2025; Gilead Sciences had 28.9% in fiscal 2025.

Which grew revenue faster, Amgen or Gilead Sciences?

In their latest fiscal years revenue changed by +10.0% at Amgen and +2.4% at Gilead Sciences.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies